Columbia Laboratories is dedicated to patient-friendly products that deliver important treatments…and are supported by scientific evidence.
Only CRINONE® 8% (progesterone gel) offers published favorable efficacy data across ALL ART procedures — in IVF-ET, donor oocyte, FET, and OI with IUI. And, only CRINONE is FDA-approved for progesterone replacement.
For more information about CRINONE click here.
Full Prescribing Information
CRINONE is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency.
The most common side effects of CRINONE include breast enlargement, constipation, somnolence, nausea, headache, and perineal pain. CRINONE is contraindicated in patients with active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thomboembolic disorders, missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease, and known or suspected malignancy of the breast or genital organs.
References: 1. Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. CRINONE vaginal gel is equally efficacious and better tolerated than intramuscular progesterone (IMP) for luteal phase progesterone support in IVF cycles: a prospective randomized study. Fertil Steril. 2009;92 (3, supp1):S243. Abstract P-551. 2. Saucedo LLE, Batiza V, Arenas L, et al. Progesterone for luteal support: randomized, prospective trial comparing vaginal and i.m. administration. Paper presented at the 19th Annual Meeting of the European Society for Human Reproduction & Embryology; July 2003; Madrid, Spain. Abstract P-383. 3. Anserini P, Costa M, Remorgida V, Sarli R, Guglielminetti E, Ragni N. Luteal phase support in assisted reproductive cycles using either vaginal (Crinone 8) or intramuscular (Prontogest) progesterone: results of a prospective, randomized study [in Italian]. Minerva Ginecol. 2001;53:297–301. 4. Coutifaris C, Patrizio P, Schafer D, Bunso S, Bucci J, Barnhart K. Is the use of Crinone for support of the luteal phase detrimental to pregnancy outcome after transfer of non-cryopreserved embryos in good prognosis patients? A preliminary report. Fertil Steril. 2000;74(suppl 1):S205. Abstract P-350. 5. Schoolcraft WB, Hesla JS, Gee MJ. Experience with progesterone gel for luteal support in a highly successful IVF programme. Hum Reprod. 2000;15:1284–1288. 6. Chantilis SJ, Zeitoun KM, Patel SI, et al. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–829. 7. Saucedo LLE, Galache VP, Hernández AS, Santos HR, Arenas ML, Patrizio P. Randomized trial of three different forms of progesterone supplementation in ART: preliminary results. Fertil Steril. 2000;74(suppl 1):S150. Abstract P-175. 8. Alper MM, Penzias AS. CRINONE offers excellent implantation rates in patients undergoing IVF. Paper presented at the 16th Annual Meeting of the European Society for Human Reproduction & Embryology; June 2000; Bologna, Italy. Abstract P-059. 9. Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, CRINONE gel and Utrogestan capsules, used for luteal support. Fertil Steril. 2007;87:83–87. 10. Geber S, Moreira AC, de Paula SO, Sampaio M. Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reprod BioMed Online. 2007;14:155–158. Available at: rbmonline.com/Article/2551. 11. Ludwig M, Schwartz P, Babahan B, et al. Luteal phase support using either CRINONE or Utrogest®: results of a prospective, randomized study. Eur J Obstet Gynecol Reprod Biol. 2002;103:48–52. 12. Doody K, Shamma N, Paulson R, Bayer S, Blake E, Yankov V. Endometrin® for luteal phase support in a randomized, controlled, open-label, prospective IVF clinical trial using a combination of Menopur® and Bravelle®. Fertil Steril. 2007;87(suppl 2):S24. Abstract P-34. 13. Berger BM, Ezcurra D, Phillips JA, Zubovskiy KY. Efficacy of three different progesterones for luteal phase and early pregnancy support in older women with high implantation potential embryos undergoing IVF-ET. Fertil Steril.2009;92 (suppl). Abstract O-76. 14. Berger B, Phillips JA. A retrospective analysis of pregnancy outcomes in recipients of anonymously donated oocytes at a large ART center. Fertil Steril. 2008;89:S11-S12. 15. Gibbons WE, Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 1998;69:96–101. 16. Williams SC, Donahue J, Muasher SJ. Vaginal progesterone therapy during programmed cycles for frozen embryo transfer: an analysis of serum progesterone levels and pregnancy rates. Fertil Steril. 2000;74(suppl 1):S209. Abstract P-363. 17. Berger BM, Phillips JA. A retrospective analysis of pregnancy outcomes in recipients of frozen/thawed embryos (FET) from donated oocytes at a large assisted reproductive technology (ART) center. Fertil Steril. 2008;90(suppl 1):S459. Abstract A-260. 18. Erdem A, Erdem M, Atmaca S, Guler I. Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study. Fertil Steril. 2009;91: 2508-2513.
